FDA Jurisdictions and Enforcement: 40+ Statistics FY2025-2026

VelSafe Insights

FDA Jurisdictions and Enforcement: 40+ Statistics From FY2025 and the AI Inspection Era

The FDA regulates approximately 78 cents of every dollar spent by U.S. consumers – covering food, drugs, biologics, medical devices, dietary supplements, cosmetics, tobacco, and veterinary products, totaling more than $3.9 trillion in goods. In FY2025, the agency conducted 694 more inspections than FY2024, issued 327 warning letters in just the second half of the year (a 73% increase), and launched Project Elsa – an AI system that analyzes compliance data, adverse event reports, and historical inspection outcomes to flag high-risk facilities before an inspector ever arrives. In May 2026, FDA announced one-day inspections for low-risk facilities powered by AI-backed risk analysis. This article compiles 40+ statistics on FDA jurisdiction scope, enforcement volume, industry-by-industry data, and what the AI inspection shift means for regulated entities.

40+ Statistics

FY2025 Enforcement Data

Project Elsa AI System

One-Day Inspections 2026

78c

Of every dollar spent by U.S. consumers falls under FDA regulatory jurisdiction – covering food, drugs, devices, biologics, supplements, cosmetics, and tobacco

FDA / Commissioner statement

+694

More inspections conducted in FY2025 versus FY2024 – across all regulated industries as FDA clears pandemic backlogs and scales AI-driven targeting

Reed Smith / Lexology, December 2025

$3.9T

In food, medical products, and tobacco products regulated by FDA domestically and internationally – per GAO’s February 2026 oversight report

GAO-26-107779, February 2026

The FDA is one of the most sweeping regulatory agencies in the United States by product scope. Its jurisdiction covers approximately 78 cents of every dollar spent by U.S. consumers – food and beverages, prescription drugs, biologics, medical devices, dietary supplements, cosmetics, tobacco products, and veterinary medicines – representing more than $3.9 trillion in goods produced domestically and imported from abroad. In FY2025, the agency conducted 694 more inspections than FY2024, issued 58 untitled letters (up from 5 in FY2024), and launched Project Elsa – an AI system that processes compliance data, adverse event reports, and inspection histories to flag high-risk facilities before an inspector arrives.

In May 2026, FDA Commissioner Dr. Martin Makary announced a new pilot program for one-day inspections for low-risk facilities powered by AI-backed risk analysis – a development that signals the agency is moving toward a tiered inspection model where AI determines depth and duration of oversight, not just facility selection. This article compiles 40+ statistics on FDA jurisdiction scope, the enforcement escalation ladder, FY2025 industry-specific data, and what the AI-driven inspection shift means for regulated entities.

Editor's Choice: Key FDA Jurisdiction and Enforcement Statistics

327

Warning letters issued by FDA in just the second half of FY2025 (July 1 to December 3, 2025) – a 73% increase over the same period in FY2024, following a brief enforcement pause at the start of the year. (Reed Smith, December 2025)

Untitled letters issued in FY2025, up from just 5 in FY2024 and 4 in FY2023 – a 1,060% increase in this previously rarely-used enforcement tool, addressing adulteration, misbranding, and objectionable conditions. (Lexology, December 2025)

June 2, 2025

Official launch date of FDA’s Project Elsa (Enterprise Language Support Assistant) – an AI system for analyzing compliance data, adverse event reports, and inspection outcomes to prioritize high-risk facility inspections. (IntuitionLabs, May 2026)

May 2026

FDA Commissioner Dr. Makary announced a pilot for one-day inspections for low-risk facilities driven by AI-backed risk analysis – the first formal acknowledgement that AI will determine inspection duration, not just facility selection. (Sidley GoodLifeSci, May 2026)

Jan 2026

FDA rolled out “agentic AI” agency-wide in January 2026 – AI systems capable of taking autonomous multi-step actions – expanding Elsa’s capabilities beyond inspection targeting to clinical protocol review, safety signal triage, and document generation. (IntuitionLabs, May 2026)

GAO High Risk

FDA medical product and food safety oversight has been on GAO’s High-Risk List since 2009 and 2007 respectively. As of December 2025, FDA had not fully implemented most of GAO’s recommendations despite agreeing with them. (GAO-26-107779, February 2026)

1. What FDA Regulates: The $3.9 Trillion Jurisdiction

FDA Jurisdiction: Major Product Categories and Primary Regulations

Food and Beverages

All food for human and animal consumption except meat, poultry, and egg products (USDA jurisdiction). Governed by FDCA and FSMA. Largest single category by product volume.

Prescription Drugs

All prescription drugs including biologics and generics. 21 CFR Parts 210-211 (cGMP). CDER reviews and approves new drug applications.

Medical Devices

Class I, II, and III devices from bandages to cardiac implants to diagnostic AI software. 21 CFR Part 820 (QMSR replacing QSR). CDRH oversees the 510(k), PMA, and De Novo pathways.

Biological Products

Vaccines, blood products, cellular therapies, gene therapies. CBER regulated under FDCA and the Public Health Service Act.

Dietary Supplements

Vitamins, minerals, herbs, and other dietary ingredients marketed as supplements. Regulated under DSHEA and 21 CFR Part 111.

Cosmetics

Personal care products, now with expanded authority under MoCRA (Modernization of Cosmetics Regulation Act, 2022). PFAS in cosmetics a 2025-26 priority.

Tobacco Products

Cigarettes, smokeless tobacco, e-cigarettes, and cigars under the Family Smoking Prevention and Tobacco Control Act. Center for Tobacco Products (CTP) oversight.

Sources: FDA.gov/what-we-do; GAO-26-107779 (February 2026); CRS Report R44576 (June 2026)

FDA regulates more than $3.9 trillion worth of food, medical products, and tobacco products produced in the U.S. and abroad, according to the GAO’s February 2026 oversight report – a figure that makes it one of the largest regulatory footprints of any federal agency. (GAO-26-107779, February 2026)
The agency’s jurisdiction spans approximately 78 cents of every dollar spent by U.S. consumers – a figure FDA commissioners have used repeatedly to illustrate the breadth of the agency’s regulatory reach across the consumer economy. (FDA Commissioner statement)
FDA’s organizational structure has six primary program-area centers: CBER, CDRH, CDER, Center for Tobacco Products (CTP), Center for Veterinary Medicine, and the Human Foods Program – along with the Office of Inspections and Investigations (OII), which was reorganized from ORA effective October 1, 2024. (CRS Report R44576, June 2026)
The MoCRA (Modernization of Cosmetics Regulation Act, 2022) significantly expanded FDA’s cosmetics authority for the first time in decades. FDA’s FY2025 budget specifically allocates funds for developing MoCRA regulations, managing compliance submission platforms, and assessing PFAS in cosmetic products. (FDA FY2025 Budget Summary)
Food and cosmetics inspections saw a 1,540 additional inspections from FY2024 to FY2025 – the largest absolute increase of any regulated industry – reflecting expanded MoCRA authority and ongoing FSMA implementation. (Reed Smith, December 2025)

2. How FDA Enforcement Works: The Escalation Ladder

The FDA Enforcement Escalation Ladder: From 483 to Injunction

FDA Form 483 (Inspectional Observations)

Issued at the end of an inspection when investigators observe conditions that may constitute violations. Not a final regulatory determination. Company has 15 business days to respond with a corrective action plan.

Untitled Letter

A formal but less severe notice for violations that do not meet the threshold for a warning letter – covering adulteration, misbranding, and objectionable conditions. FDA issued 58 untitled letters in FY2025 versus 5 in FY2024. Recipients must respond within 30 workdays.

Warning Letter

FDA’s primary enforcement tool for significant violations. Publicly posted on FDA.gov. Response required within 15 business days. Failure to respond adequately can trigger escalation to injunction or import alert. 303 drug/biologics warning letters issued in FY2025.

Import Alert

Allows FDA to detain products from a facility without physical examination – effectively blocking imports from a non-compliant foreign manufacturer. 75 new import alerts issued in FY2024, with 65% targeting OTC manufacturers. Major enforcement tool for China and India sites.

Injunction, Seizure, Consent Decree, or Criminal Prosecution

The most severe enforcement tools, requiring Department of Justice involvement. Consent decrees impose binding operational restrictions and can require remediation under FDA-supervised oversight for years.

Sources: FDA Enforcement Tools (FDA.gov); Hogan Lovells (September 2025); Lexology (December 2025)

The escalation from 483 to warning letter is not automatic. FDA evaluates the Inspection Classification (NAI, VAI, or OAI) after the establishment inspection report is completed. OAI (Official Action Indicated) classifications trigger potential warning letter issuance, while NAI (No Action Indicated) and VAI (Voluntary Action Indicated) typically do not. (FDA enforcement framework)
The sharp increase in untitled letters in FY2025 – from 5 to 58 – represents a significant enforcement posture shift. Untitled letters are used when FDA believes a violation is real but does not yet warrant the formal warning letter threshold. The 11-fold increase suggests FDA is moving faster to establish a formal enforcement record before escalating. (Lexology, December 2025; Reed Smith, December 2025)
Under the 2025 enforcement framework, Remote Regulatory Assessments (RRAs) are explicitly not considered inspections under sections 704(a)(1) of the FDCA, per FDA’s June 2025 guidance. They may inform regulatory decisions but cannot independently trigger enforcement escalation that requires physical inspection authority. (Pharmaceutical Online, March 2026, citing June 2025 FDA guidance)
Import alert authority under 21 U.S.C. Section 381 allows FDA to detain products from a facility without physical examination at the port of entry – making it one of the most commercially impactful enforcement tools available to the agency. Removal from an import alert typically requires demonstrating sustained corrective action through an independent audit. (FDA import alert authority)

3. The Three Inspection Classifications: NAI, VAI, OAI

NAI – No Action Indicated

No objectionable conditions or practices were found, or any observed deviations were minor enough not to justify follow-up regulatory action. The inspection closes with no enforcement consequence.

VAI – Voluntary Action Indicated

Objectionable conditions or practices were found and noted in a Form 483, but the violations are not significant enough to justify formal regulatory action. The company is expected to correct them voluntarily.

OAI – Official Action Indicated

Significant violations were found that may constitute regulatory action. The OAI classification is what triggers FDA’s consideration of warning letters, import alerts, injunctions, or other formal enforcement tools.

In FY2024, 93% of inspected sites achieved NAI or VAI classification in the pharmaceutical quality dataset – meaning enforcement action was recommended in approximately 7% of drug quality inspections. However, that 7% OAI rate against 989 inspections generated the 105 drug warning letters that represented a five-year high. (FDA FY2024 State of Pharmaceutical Quality Report)
Inspection classifications are not the same as 483 issuance. A VAI facility can receive 483 observations that are subsequently resolved to VAI through the response and review process. An OAI classification reflects FDA’s conclusion that the violations cannot be adequately addressed through voluntary corrective action alone. (FDA inspection classification guidance)
With Project Elsa now targeting high-risk facilities, the composition of the inspected population is shifting. If Elsa successfully identifies higher-risk sites for inspection, the OAI rate per inspection should increase as inspections are concentrated at facilities with actual compliance issues rather than distributed across random or low-risk populations. (IntuitionLabs, May 2026)

4. Project Elsa: FDA's AI-Driven Inspection Targeting System

Project Elsa Timeline: From Concept to Agency-Wide AI (2025-2026)

Early 2025

White House directive encouraging federal agencies to adopt generative AI for efficiency accelerates Elsa’s development timeline. FDA begins internal testing.

June 2, 2025

FDA officially announces Project Elsa (Enterprise Language Support Assistant) via press release. Described as an assistant for employees across the agency, with initial applications in clinical protocol review, safety signal triage, and inspection targeting.

H2 2025

Elsa deployed for inspection targeting: processes compliance data, adverse event reports, and historical inspection outcomes to flag high-risk facilities. Foreign manufacturers in China and India subject to increased unannounced inspection frequency.

January 2026

FDA rolls out “agentic AI” agency-wide – AI systems capable of taking autonomous multi-step actions, not just answering queries – expanding Elsa’s capabilities to document generation and automated safety signal analysis.

May 2026

Commissioner Makary announces “one-day inspections” pilot for low-risk facilities, AI-backed risk analysis determines inspection duration as well as facility selection. Second version of Elsa launched.

Sources: IntuitionLabs (May 2026); Sidley GoodLifeSci (May 2026); Hogan Lovells (September 2025); Reed Smith (December 2025)

Elsa (Enterprise Language Support Assistant) was officially launched by FDA on June 2, 2025, following a White House directive encouraging federal agencies to adopt generative AI. The system is designed to sift through a company’s entire electronic compliance data footprint in minutes, highlighting patterns such as repeat deviation categories, adverse event clustering, and inspection history gaps. (IntuitionLabs, May 2026; Hogan Lovells, September 2025)
According to FDA sources and industry analyses, Elsa analyzes complaint data, adverse event reports, and historical inspection outcomes to prioritize inspections and Remote Regulatory Assessments. Manufacturers with unresolved CAPAs or inconsistent documentation are being flagged earlier and more often than under the previous risk-based scheduling approach. (Hogan Lovells, September 2025)
In January 2026, FDA rolled out “agentic AI” across the agency – systems capable of taking autonomous multi-step actions, not just answering single queries. This represents a significant expansion from Elsa’s initial inspection-targeting function to broader operational automation including document drafting and safety signal triage. (IntuitionLabs, May 2026; Sidley GoodLifeSci, May 2026)
In May 2026, FDA Commissioner Makary announced a new pilot for “one-day inspections” for low-risk facilities driven by AI-backed risk analysis – the first formal acknowledgement that AI will determine inspection duration, not just facility selection. This creates a tiered inspection model where Elsa’s risk score influences both whether a facility gets inspected and how long the inspection lasts. (Sidley GoodLifeSci, May 2026)
FDA has stated that no enforcement action is ever based solely on AI analysis without human review. However, some career inspectors and reviewers raised concerns during internal town halls about over-reliance on AI and potential liability if AI-generated risk assessments lead to missed violations at lower-risk-rated facilities. (IntuitionLabs, May 2026)

5. FY2025 Enforcement by Industry: Drugs, Devices, Food, and Biologics

Drugs: Largest Warning Letter Spike

303 drug/biologics warning letters in FY2025 vs 190 in FY2024 (+59%). The drug industry recorded 82 more warning letters than the prior year. September 9, 2025 advertising crackdown issued 60+ letters in a single day.

Devices: Five-Year Acceleration

Device-specific quality system enforcement letters rose from 6 (2021) to 30 (2025). Approximately 54 device warning letters in 2025 (17% increase from 46 in 2024). QMSR transition changed vocabulary but not violation patterns.

Food and Cosmetics: Largest Inspection Increase

1,540 more inspections from FY2024 to FY2025 in this sector – the largest absolute volume increase. Driven by MoCRA cosmetics authority expansion and FSMA implementation continuing.

All Four Industries: Heightened Oversight

Reed Smith December 2025 review confirms all four regulated industry categories – drugs, devices, biologics, food and cosmetics – experienced heightened FDA oversight in FY2025, whether through increased warning letters, expanded inspections, or both.

Following a brief enforcement pause at the start of 2025, the FDA significantly accelerated warning letter issuance. 327 warning letters were issued from July 1 to December 3, 2025 – a 73% increase over the same period in FY2024. The pause and resumption pattern means organizations that reduced compliance investment during the pause are now at elevated risk. (Reed Smith, December 2025)
The drug industry’s FY2025 warning letter surge was partly driven by the September 9, 2025 crackdown on deceptive drug advertising, when FDA issued over 60 warning letters in a single day. This enforcement action is specifically noted as a concentrated event rather than a sustained baseline – the underlying drug quality warning letter trajectory remains upward independent of this event. (Reed Smith, December 2025)
For medical devices, the transition from QSR (Quality System Regulation) to QMSR (Quality Management System Regulation) – aligning 21 CFR Part 820 with ISO 13485:2016 – has changed how FDA frames inspection observations but not the underlying violation rate. Investigators are already informally benchmarking device quality systems against ISO standards even before the final QMSR compliance date. (Hogan Lovells, September 2025)
FDA’s FY2024 pharmaceutical data showed 75 new import alerts, with 65% targeting OTC manufacturers and the largest shares going to sites in China (39%), India (13%), and Europe (13%). With Elsa now targeting foreign sites with AI-assisted risk analysis and unannounced inspections, import alert activity in FY2025-26 is expected to continue or exceed FY2024 levels. (FDA FY2024 Quality Report; GMP-Publishing, 2025)

6. Foreign Site Scrutiny and GAO's Assessment of FDA Capacity

62%

of drug quality inspections at foreign sites in FY2024 (all-time high) as FDA expands international oversight

FDA FY2024 Quality Report

GAO High Risk since 2009

FDA medical product oversight has been on GAO’s High-Risk List since 2009; food safety since 2007

GAO-26-107779, Feb 2026

Most GAO recs unimplemented

As of December 2025, FDA had agreed with but not yet fully implemented most GAO recommendations from its oversight review

GAO-26-107779, Feb 2026

FDA has expanded its use of unannounced inspections at foreign manufacturing facilities – particularly in China and India – to ensure they meet U.S. standards. Foreign manufacturers who have historically had advance notice of FDA inspections are now experiencing the same unannounced inspection approach that applies to domestic facilities. (Reed Smith, December 2025; Hogan Lovells, September 2025)
GAO’s February 2026 report (GAO-26-107779) reviewing FDA’s capacity from FY2008 through FY2024 confirmed that FDA medical product oversight has been on GAO’s High-Risk List since 2009 and food safety since 2007 – reflecting longstanding capacity concerns that have not been fully resolved. (GAO-26-107779, February 2026)
The same GAO report identified continuing challenges with FDA’s capacity to recruit, retain, and train staff – and found that as of December 2025, FDA had agreed with but had not yet fully implemented most of GAO’s recommendations from prior reports. In early 2025, FDA officials also told GAO that the agency’s strategic workforce plan was “no longer current.” (GAO-26-107779, February 2026)
The tension between expanding inspection volume (694 more inspections in FY2025) and documented staffing capacity challenges creates a specific risk for regulated entities: inspections that are more numerous but staffed by less-experienced investigators may produce more variable 483 observations, making strong 483 response programs even more important as the first line of defense. (GAO-26-107779; Reed Smith, 2025)

7. What the Enforcement Data Means for Regulated Entities in 2025-26

Enforcement pause is over – FY2025 surge is the new baseline

Elsa can see your compliance history before the inspector arrives

Unannounced inspections expanding internationally

One-day inspections mean AI determines depth of review

Untitled letters are now a real first escalation step

The most important operational implication of the Elsa system: FDA’s inspector knows what your compliance data shows before they arrive at your facility. Unresolved CAPAs, adverse event patterns, and documentation inconsistencies are being flagged before the inspection visit, not discovered during it. The inspection itself becomes a confirmation, not an investigation. (Hogan Lovells, September 2025)
The brief enforcement pause in early 2025 followed by a 73% warning letter surge in H2 2025 establishes a clear pattern: organizations that used the pause period to delay quality system investment are now facing accelerated enforcement risk. The baseline is not the pause; it is the post-pause acceleration. (Reed Smith, December 2025)
The one-day inspection pilot announced in May 2026 creates a new compliance risk: a facility rated “low risk” by Elsa that receives a one-day inspection instead of a multi-day inspection has less inspector time to establish its compliance context. If a violation is found within the one-day window, there is no subsequent day for context mitigation. Preparation for short inspections requires more rigorous readiness, not less. (Sidley GoodLifeSci, May 2026)
The MoCRA expansion for cosmetics means that cosmetic manufacturers who previously operated outside meaningful FDA inspection scrutiny now face an inspection infrastructure that is expanding in exactly the same year that Elsa is being deployed – creating an elevated first-inspection risk for companies that have not previously prepared for FDA inspection. (FDA FY2025 Budget; MoCRA regulatory implementation)

Key Takeaways for Regulated Entities and Quality Teams

FDA’s AI can see your compliance posture before the inspector can

Project Elsa processes compliance data, adverse event reports, and historical inspection outcomes to flag high-risk facilities. Manufacturers with open CAPAs, adverse event clusters, or inconsistent documentation are being identified and prioritized before physical inspection. The data environment that triggers an inspection visit now includes everything FDA already has on file – and Elsa can analyze it faster than any inspection team.

The enforcement pause is over – 73% surge in H2 2025 is the trajectory

327 warning letters in just six months (July-December 2025), 58 untitled letters versus 5 in FY2024, 303 drug/biologics warning letters for the full year (+59%). The brief early-2025 pause was not a policy shift. It was followed by the highest H2 enforcement volume in years. Organizations that moderated compliance investment during the pause should treat FY2025 H2 as their planning baseline.

Untitled letters are now a real enforcement step – not a rarity

FDA issued 58 untitled letters in FY2025 versus 5 in FY2024 – an 1,060% increase. These letters address adulteration, misbranding, and objectionable conditions that do not yet meet the warning letter threshold. The surge signals FDA is building enforcement records faster and at lower violation thresholds than historically. Recipients have 30 workdays to respond. Organizations that receive untitled letters should treat them as warning letter precursors, not minor communications.

Foreign manufacturers face unannounced inspection expansion

FDA has expanded unannounced inspections to foreign manufacturing facilities – particularly in China and India – removing the advance notice that historically allowed foreign sites to prepare more than domestic manufacturers. With Elsa targeting high-risk facilities and 62% of drug quality inspections already at foreign sites (all-time high in FY2024), the risk for non-U.S. manufacturers supplying the U.S. market is materially higher than in pre-AI, pre-Elsa inspection cycles.

One-day inspections require more readiness, not less

The May 2026 one-day inspection pilot for low-risk facilities is not a sign of reduced scrutiny. An inspector with one day has no time to establish context or review mitigating factors. A single finding in a compressed inspection window carries the same enforcement weight as a finding in a multi-day inspection. Low-risk ratings from Elsa require active maintenance – facilities with favorable risk profiles that allow CAPA or documentation gaps to accumulate may find themselves reclassified into the higher-risk, longer-inspection tier.

GAO capacity concerns add variability to the inspection environment

GAO’s February 2026 report confirms FDA faces ongoing staffing challenges – recruiting, retaining, and training inspectors – with most GAO recommendations unimplemented as of December 2025. A larger inspection workforce operating under staffing pressure may produce more variable 483 observations. Strong 483 response programs – identifying root cause, specifying CAPA with timelines, addressing systemic issues – become more important as the inspectorate expands and experience levels vary.

Sources

Government Sources

Industry and Legal Sources